Department of Medicine, School of Medicine, University of São Paulo, São Paulo, Brazil.
Am J Physiol Lung Cell Mol Physiol. 2012 Dec 1;303(11):L939-52. doi: 10.1152/ajplung.00034.2012. Epub 2012 Sep 21.
Several studies have demonstrated the importance of Rho-kinase in the modulation of smooth muscle contraction, airway hyperresponsiveness, and inflammation. However, the effects of repeated treatment with a specific inhibitor of this pathway have not been previously investigated. We evaluated the effects of repeated treatment with Y-27632, a highly selective Rho-kinase inhibitor, on airway hyperresponsiveness, oxidative stress activation, extracellular matrix remodeling, eosinophilic inflammation, and cytokine expression in an animal model of chronic airway inflammation. Guinea pigs were subjected to seven ovalbumin or saline exposures. The treatment with Y-27632 (1 mM) started at the fifth inhalation. Seventy-two hours after the seventh inhalation, the animals' pulmonary mechanics were evaluated, and exhaled nitric oxide (E(NO)) was collected. The lungs were removed, and histological analysis was performed using morphometry. Treatment with Y-27632 in sensitized animals reduced E(NO) concentrations, maximal responses of resistance, elastance of the respiratory system, eosinophil counts, collagen and elastic fiber contents, the numbers of cells positive for IL-2, IL-4, IL-5, IL-13, inducible nitric oxide synthase, matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1, transforming growth factor-β, NF-κB, IFN-γ, and 8-iso-prostaglandin F2α contents compared with the untreated group (P < 0.05). We observed positive correlations among the functional responses and inflammation, remodeling, and oxidative stress pathway activation markers evaluated. In conclusion, Rho-kinase pathway activation contributes to the potentiation of the hyperresponsiveness, inflammation, the extracellular matrix remodeling process, and oxidative stress activation. These results suggest that Rho-kinase inhibitors represent potential pharmacological tools for the control of asthma.
几项研究表明 Rho-激酶在调节平滑肌收缩、气道高反应性和炎症方面的重要性。然而,以前并未研究过该途径的特异性抑制剂重复治疗的效果。我们评估了 Rho-激酶抑制剂 Y-27632 重复治疗对慢性气道炎症动物模型中气道高反应性、氧化应激激活、细胞外基质重塑、嗜酸性粒细胞炎症和细胞因子表达的影响。豚鼠接受了 7 次卵白蛋白或生理盐水暴露。从第 5 次吸入开始给予 Y-27632(1mM)治疗。在第 7 次吸入后 72 小时,评估动物的肺力学并收集呼出的一氧化氮(E(NO))。取出肺组织并进行形态计量学分析。在致敏动物中用 Y-27632 治疗可降低 E(NO)浓度、阻力的最大反应、呼吸系统的弹性、嗜酸性粒细胞计数、胶原和弹性纤维含量、IL-2、IL-4、IL-5、IL-13、诱导型一氧化氮合酶、基质金属蛋白酶-9、金属蛋白酶组织抑制剂-1、转化生长因子-β、NF-κB、IFN-γ和 8-异前列腺素 F2α含量阳性的细胞数与未治疗组相比(P<0.05)。我们观察到功能反应与炎症、重塑和氧化应激途径激活标志物之间存在正相关。总之,Rho-激酶途径的激活有助于增强高反应性、炎症、细胞外基质重塑过程和氧化应激激活。这些结果表明 Rho-激酶抑制剂可能是控制哮喘的潜在药物工具。